natgillin/translations-raw huggingface dataset:
• if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. 
• če jemljete katero od naslednjih zdravil, ki se uporabljajo za zdravljenje visokega krvnega tlaka: - zaviralec ACE (na primer enalapril, lizinopril ali ramipril), zlasti če imate kakšne težave z ledvicami, ki so povezane s sladkorno boleznijo - aliskiren.
The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to < 18 years (body weight ≥ 20 kg and ≤ 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period. 
Učinek dveh odmerkov telmisartana na znižanje krvnega tlaka so ocenili pri 76 hipertenzivnih bolnikih, starih 6 do < 18 let , pretežno s preveliko telesno maso (telesna masa  20 kg in 120 kg, povprečna 74,6 kg), po štiritedenskem zdravljenju s telmisartanom po 1 mg/kg (n = 29 zdravljenih) ali 2 mg/kg (n = 31 zdravljenih).
Try to take the tablet at the same time each day. 
Priporočeni odmerek je ena tableta na dan. Poskusite tablete jemati vsak dan ob isti uri.
Possible side effects of Kinzalmono 
Možni neželeni učinki zdravila Kinzalmono so
Kinzalmono is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Zdravilo Kinzalmono v zgodnji nosečnosti ne priporočajo; ne smete pa ga jemati, ko boste noseči več kot 3 mesece, ker lahko po tretjem mesecu nosečnosti resno škoduje vašemu otroku.
QUALITATIVE AND QUANTITATIVE COMPOSITION Kinzalmono 20 mg tablets 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Kinzalmono 20 mg tablete
Kinzalmono is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Če boste želeli dojiti, bo zdravnik za vas izbral drugo zdravilo, še zlasti, če je vaš otrok novorojenček ali se je prezgodaj rodil.
How to take Kinzalmono 
Kako jemati zdravilo Kinzalmono
Kinzalmono 40 mg and 80 mg tablets 4 years 
Kinzalmono 40 mg in 80 mg tablete 4 leta
• Diuretics ('water tablets'), especially if taken in high doses together with Kinzalmono, may lead to excessive loss of body water and low blood pressure (hypotension). 
• diuretiki (tablete za odvajanje vode), zlasti če jemljete velike odmerke sočasno z zdravilom Kinzalmono, ki lahko povzročijo preveliko izgubo vode iz telesa in znižajo krvni tlak (povzročijo hipotenzijo)
For treatment of high blood pressure, the usual dose of Kinzalmono for most patients is one 40 mg tablet once a day to control blood pressure over the 24-hour period. 
Za zdravljenje visokega krvnega tlaka je pri večini bolnikov običajni odmerek zdravila Kinzalmono za 24-urni nadzor krvnega tlaka ena tableta po 40 mg enkrat na dan.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte zdravnikom ali farmacevtom.
(It is also better to avoid Kinzalmono in early pregnancy - see pregnancy section.) 
• če ste noseči več kot 3 mesece (zdravilu Kinzalmono se je bolje izogibati tudi v zgodnji nosečnosti - glejte poglavje o nosečnosti),
Kinzalmono 20 mg tablets Pack sizes: Blister with 14, 28, 56 or 98 tablets. 
Kinzalmono 20 mg tablete Velikost pakiranja: pretisni omot po14, 28, 56 ali 98 tablet.
Back pain (e.g. sciatica), muscle spasms, myalgia, Arthralgia, pain in extremity, tendon pain (tendinitis like symptoms) 
bolečina v hrbtu (npr. išias), mišični krči, mialgija artralgija,bolečine v okončini, bolečina v kitah (tendinitisu podobni simptomi)
INFORMATION IN BRAILLE Kinzalmono 40 mg 
PODATKI V BRAILLOVI PISAVI Kinzalmono 40 mg
Kinzalmono should be used only with caution in patients with mild to moderate hepatic impairment. 
Zdravilo Kinzalmono moramo previdno dajati bolnikom z zmerno hudo do hudo jetrno okvaro.
What Kinzalmono contains 
Kaj vsebuje zdravilo Kinzalmono
Talk to your doctor before taking Kinzalmono: 
Pred začetkom jemanja zdravila Kinzalmono se posvetujte z zdravnikom:
INFORMATION IN BRAILLE Kinzalmono 20 mg 
PODATKI V BRAILLOVI PISAVI Kinzalmono 20 mg
However, sometimes your doctor may recommend a lower dose of 20 mg or a higher dose of 80 mg. Alternatively, Kinzalmono may be used in combination with diuretics ('water tablets') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Kinzalmono. 
Kadar s priporočenim odmerkom ne dosežemo želenega znižanja krvnega tlaka, lahko odmerek telmisartana povečamo do največ 80 mg enkrat na dan. Telmisartan lahko uporabljamo tudi v kombinaciji s tiazidnimi diuretiki, kot je npr. hidroklorotiazid, za katerega se je pokazalo, da ima v kombinaciji s telmisartanom aditivni učinek na znižanje krvnega tlaka.
Kinzalmono may also be used in combination with diuretics ('water tablets') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Kinzalmono. 
Zdravilo Kinzalmono lahko jemljete tudi v kombinaciji z diuretiki, kot je hidroklorotiazid, za katerega se je pokazalo, da pri sočasnem jemanju z zdravilom Kinzalmono dodatno znižuje krvni tlak.
Kinzalmono 20 mg tablets 3 years 
Kinzalmono 20 mg tablete 3 leta
Such conditions should be corrected before the administration of Kinzalmono. 
Tovrstna stanja moramo uravnati pred zdravljenjem z zdravilom Kinzalmono.
INFORMATION IN BRAILLE Kinzalmono 80 mg 
PODATKI V BRAILLOVI PISAVI Kinzalmono 80 mg
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). 
Znano je, da izpostavljenost antagonistom angiotenzina II v drugem in tretjem trimesečju nosečnosti lahko povzroči fetotoksične učinke pri človeku (zmanjšano delovanje ledvic, oligohidramnij, zapoznela zakostenitev lobanje) in toksične učinke pri novorojenčku (ledvična odpoved, hipotenzija, hiperkaliemija) (glejte poglavje 5.3).
Volume and/or sodium depletion should be corrected prior to administration of Kinzalmono. 
Pomanjkanje volumna ali natrija ali obe stanji moramo uravnati pred začetkom zdravljenja z zdravilom Kinzalmono.
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non-steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim). 
Tveganje je lahko povečano pri kombiniranem zdravljenju z drugimi zdravili, ki lahko povzročijo hiperkaliemijo (nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Unit dose blister (28 x 1 tablets pack) 
Pretisni omot za enkratni odmerek (28 x 1 tableta)
The overall incidence of adverse reactions reported with telmisartan (was usually comparable to placebo (41.4 % vs 43.9 %) in controlled trials in patients treated for hypertension. 
V s placebom nadzorovanih kliničnih preskušanjih pri bolnikih, ki so se zdravili zaradi hipertenzije, je bila skupna pogostnost neželenih dogodkov podobna pri telmisartanu in placebu (41,4 % v primerjavi s 43,9 %).
Eye disorders: Rare: 
Očesne bolezni Redki:
Kinzalmono 40 mg tablets White oblong tablets of 3.8 mm engraved with the code number '51H' on one side. 
Bele, 3,8 mm podolgovate tablete z vtisnjeno kodno številko 51H na eni strani.
You must tell your doctor if you think you are (or might become) pregnant. 
Obvestite zdravnika, če menite, da ste noseči ali načrtujete zanositev.
Kinzalmono 20 mg tablets EU/1/98/091/009 (14 tablets) EU/1/98/091/010 (28 tablets) EU/1/98/091/011 (56 tablets) EU/1/98/091/012 (98 tablets) 
Kinzalmono 20 mg tablete EU/1/98/091/009 (14 tablet) EU/1/98/091/010 (28 tablet) EU/1/98/091/011 (56 tablet) EU/1/98/091/012 (98 tablet)
Kinzalmono is available in blister packs containing 14, 28, 56 or 98 tablets. 
Zdravilo Kinzalmono je na voljo v pretisnih omotih po 14, 28, 56 ali 98 tablet.
There is no experience regarding the administration of Kinzalmono in patients with recent kidney transplantation. 
Pri bolnikih z nedavno presajeno ledvico ni izkušenj z uporabo zdravila Kinzalmono.
Kinzalmono 40 mg tablets EU/1/98/091/001 (14 tablets) EU/1/98/091/002 (28 tablets) EU/1/98/091/003 (56 tablets) EU/1/98/091/004 (98 tablets) EU/1/98/091/013 (28 x 1 tablets) 
Kinzalmono 40 mg tablete EU/1/98/091/001 (14 tablet) EU/1/98/091/002 (28 tablet) EU/1/98/091/003 (56 tablet) EU/1/98/091/004 (98 tablet) EU/1/98/091/013 (28 x 1 tableta)
What Kinzalmono looks like and contents of the pack Kinzalmono 40 mg tablets are white, oblong-shaped and engraved with the code number '51H' on one side. 
Izgled zdravila Kinzalmono in vsebina pakiranja Tablete Kinzalmono 40 mg so bele, podolgovate tablete z vtisnjenim logom podjetja in oznako 51H..
Kinzalmono 80 mg tablets White oblong tablets of 4.6 mm engraved with the code number '52H' on one side. 
Bele, 4,6 mm podolgovate tablete z vtisnjeno kodno številko 52H na eni strani.
Kinzalmono 80 mg tablets EU/1/98/091/005 (14 tablets) EU/1/98/091/006 (28 tablets) EU/1/98/091/007 (56 tablets) EU/1/98/091/008 (98 tablets) EU/1/98/091/014 (28 x 1 tablets) 
Kinzalmono 80 mg tablete EU/1/98/091/005 (14 tablet) EU/1/98/091/006 (28 tablet) EU/1/98/091/007 (56 tablet) EU/1/98/091/008 (98 tablet) EU/1/98/091/014 (28 x 1 tableta)
NAME OF THE MEDICINAL PRODUCT Kinzalmono 40 mg tablets telmisartan 
IME ZDRAVILA Kinzalmono 40 mg tablete telmisartan
What Kinzalmono looks like and contents of the pack Kinzalmono 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side. 
Izgled zdravila Kinzalmono in vsebina pakiranja Tablete Kinzalmono 20 mg so bele, okrogle tablete z vtisnjenim logom podjetja in oznako 50H .
How to store Kinzalmono 
Shranjevanje zdravila Kinzalmono
NAME OF THE MEDICINAL PRODUCT Kinzalmono 80 mg tablets telmisartan 
IME ZDRAVILA Kinzalmono 80 mg tablete telmisartan
At the beginning of the preventive therapy with Kinzalmono 80 mg, blood pressure should be frequently monitored. 
Za zmanjševanje srčnožilnih dogodkov je običajni odmerek zdravila Kinzalmono ena tableta po 80 mg na dan. Na začetku preventivnega zdravljenja z zdravilom Kinzalmono 80 mg je treba pogosto izmeriti krvni tlak.
Symptomatic hypotension, especially after the first dose of Kinzalmono, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting. 
Pri bolnikih z zmanjšanim volumnom krvi in/ali zmanjšano količino natrija zaradi intenzivnega diuretičnega zdravljenja, omejitve količine soli v hrani, driske ali bruhanja, se zlasti po prvem odmerku zdravila Kinzalmono lahko pojavi simptomatska hipotenzija.
NAME OF THE MEDICINAL PRODUCT Kinzalmono 20 mg tablets telmisartan 
IME ZDRAVILA Kinzalmono 20 mg tablete telmisartan
What Kinzalmono looks like and contents of the pack Kinzalmono 80 mg tablets are white, oblong-shaped and engraved with the code number '52H' on one side. 
Izgled zdravila Kinzalmono in vsebina pakiranja Tablete Kinzalmono so bele, podolgovate tablete z vtisnjenim logom podjetja in oznako 52H.
Kinzalmono 40 mg and 80 mg tablets Pack sizes: Blister with 14, 28, 56 or 98 tablets or perforated unit dose blisters with 28 x 1 tablets. 
Velikost pakiranja: pretisni omot po 14, 28, 56 ali 98 tablet ali perforirani pretisni omoti za enkratni odmerek po 28 x 1 tableta.
Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood. 
Občasni neželeni učinki (pojavijo se pri največ 1 od 100 bolnikov): okužbe sečil, okužbe zgornjih dihal (npr. bolečine v grlu, vneti sinusi, prehlad), pomanjkanje rdečih krvničk (anemija), visoka raven kalija, težave z uspavanjem, občutek žalosti (depresija), omedlevica (sinkopa), vrtoglavica, počasen srčni utrip (bradikardija), nizek krvni tlak (hipotenzija) pri osebah, ki se zdravijo zaradi visokega krvnega tlaka, omotica pri vstajanju (ortostatska hipotenzija), zasoplost, kašelj, trebušne bolečine, driska, nelagodje v trebuhu, napenjanje, bruhanje, srbež, povečano znojenje, medikamentni izpuščaj, bolečine v hrbtu, mišični krči, mišična bolečina (mialgija), ledvična okvara, tudi akutna ledvična odpoved, bolečina v prsnem košu, občutek oslabelosti in zvišana raven kreatinina v krvi.
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), severe allergic reaction (anaphylactic reaction), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), upset stomach, dry mouth, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood. 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): sepsa* (pogosto poimenovana tudi zastrupitev krvi, je huda okužba, pri kateri pride v vsem telesu do vnetnega odziva in je lahko usodna), povečanje določenih belih krvničk (eozinofilija), majhno število trombocitov (trombocitopenija), huda alergijska reakcija (anafilaktična reakcija), alergijska reakcija (npr. izpuščaj, srbež, oteženo dihanje, piskanje, otekanje obraza ali nizek krvni tlak), nizka raven krvnega sladkorja (pri bolnikih s sladkorno boleznijo), občutek tesnobe, zaspanost, motnje vida, hitro bitje srca (tahikardija), suha usta, želodčne težave, motnje okusa (disgevzija), motnje v delovanju jeter (pri japonskih bolnikih obstaja večja verjetnost pojavljanja tega neželenega učinka), hitro otekanje kože in sluznice, ki lahko povzroči tudi smrt (angioedem tudi s smrtnim izidom), ekcem (kožno obolenje), kožna rdečica, izpuščaji (urtikarija), hud medikamentni izpuščaj, bolečina v sklepih (artralgija), bolečina v okončini, bolečina v kitah, gripi podobna bolezen, znižan hemoglobin (krvna beljakovina), zvišana raven sečne kisline, zvišana raven jetrnih encimov ali kreatin fosfokinaze v krvi.
Progressive scarring of lung tissue (interstitial lung disease)**. 
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): Progresivno brazgotinjenje pljučnega tkiva (intersticijska pljučna bolezen)**
Kinzalmono is available in blister packs containing 14, 28, 56 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets. 
Kinzalmono je na voljo v pretisnih omotih po 14, 28, 28 x 1, 56 ali 98 tablet.
It must not be given to patients with active cancers. 
Ne sme se dajati bolnikom z aktivnim rakom.
This treatment course is repeated one year later. 
Ta cikel zdravljenja se ponovi čez eno leto.
The first year, patients take one to two tablets a day for 4 or 5 days; after one month, they again take one to two tablets a day for 4 or 5 days, adding up to a total dose of 1.75 mg per kg body weight over the two periods. 
Prvo leto bolniki 4 do 5 dni zaporedoma jemljejo eno do dve tableti na dan; po enem mesecu ponovno 4 do 5 dni jemljejo eno do dve tableti na dan, tako da skupni odmerek znaša 1,75 mg na kg telesne mase v dveh obdobjih.
The full EPAR for Mavenclad can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Mavenclad je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Mavenclad. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Mavenclad.
What measures are being taken to ensure the safe and effective use of Mavenclad? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Mavenclad?
The European Medicines Agency therefore decided that Mavenclad's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Mavenclad večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
Mavenclad is used in patients whose disease is highly active. 
Zdravilo Mavenclad se uporablja pri bolnikih, pri katerih je bolezen zelo aktivna.
Cladribine is already approved in the EU for the treatment of certain leukaemias (cancers affecting lymphocytes). 
Kladribin je v EU že odobren za zdravljenje nekaterih levkemij (rakov, ki prizadenejo limfocite).
In addition, the fact that Mavenclad is given by mouth, and requires only 2 short courses 12 months apart, offers an advantage to patients. 
Poleg tega tudi to, da se zdravilo Mavenclad daje peroralno in sta potrebna le dva kratka cikla v razmiku 12 mesecev, predstavlja prednost za bolnike.
The results suggested that the effects were greatest in patients with highly active disease and that benefit might be expected in other relapsing forms of multiple sclerosis. 
Rezultati so nakazali, da so bili učinki največji pri bolnikih z visoko aktivno boleznijo in da bi korist lahko pričakovali tudi pri drugih recidivnih oblikah multiple skleroze.
In a follow-up study for up to a further 2 years, benefit of the original treatment was maintained but there seemed no additional benefit from giving more than 2 courses of Mavenclad treatment. 
V kontrolni študiji, ki je trajala največ nadaljnji dve leti, so se koristi prvotnega zdravljenja ohranile, ni pa kazalo na dodatno korist več kot dveh ciklov zdravljenja z zdravilom Mavenclad.
Relapsing means that the patient has repeated flare-ups of the symptoms. 
Recidivna pomeni, da imajo bolniki ponavljajoče se izbruhe simptomov.
Rashes, hair loss and lowered counts of another type of white blood cell, neutrophils, may also affect up to 1 patient in 10. 
Izpuščaji, izpadanje las in dlak ter znižano število druge vrste belih krvnih celic, nevtrofilcev, se lahko pojavijo pri največ 1 bolniku od 10.
This appeared to be most marked in patients with highly active disease, in whom the clinical benefits were considered to outweigh the risks of a severe long-term lowering in lymphocyte numbers, which increases the risk of infection and possibly of cancer. 
To se je najizraziteje pokazalo pri bolnikih z zelo aktivno boleznijo, pri katerih je bilo ocenjeno, da klinične koristi odtehtajo tveganja dolgotrajnega znižanja števila limfocitov, zaradi katerega se poveča tveganje za okužbo in morda za rak.
Treatment must also be avoided in patients whose kidney function is moderately or severely reduced, and in women who are pregnant or breast feeding. 
Izogibati se mu je treba tudi pri bolnikih z zmerno ali hudo okvaro delovanja ledvic in pri ženskah, ki so noseče ali dojijo.
The active substance in Mavenclad, cladribine, has a similar chemical structure to purine, one of the substances needed to make up the DNA. 
Zdravilna učinkovina v zdravilu Mavenclad, kladribin, ima podobno kemično strukturo kot purin, ena od snovi, ki so potrebne za izgradnjo DNK.
Effects on lymphocytes reduce the body's immune defence against infections and cancer: Mavenclad must not be given to patients with active long-term infections such as tuberculosis or hepatitis, nor to patients with HIV infection or whose immune defences are weakened for other reasons such as treatment with medicines that suppress the immune system. 
Učinki na limfocite zmanjšujejo imunsko obrambo telesa pred okužbami in rakom: zdravila Mavenclad se ne sme dajati bolnikom z aktivnimi dolgotrajnimi okužbami, kot je tuberkuloza ali hepatitis, ali bolnikom, okuženim z virusom HIV ali pri katerih je imunski odziv oslabljen iz drugih razlogov, npr. zaradi zdravljenja z zdravili, ki zavirajo imunski sistem.
Other information about Mavenclad 
Druge informacije o zdravilu Mavenclad
The company that markets Mavenclad will provide information on the medicine for healthcare professionals and patients, including advice on the side effects and safety concerns, the need for monitoring before and during treatment, and on pregnancy prevention and effective contraception in both female and male patients. 
Družba, ki trži zdravilo Mavenclad, bo zagotovila informacije o zdravilu za zdravstvene delavce in bolnike, vključno z nasveti o neželenih učinkih in zadržkih glede varnosti, potrebi po spremljanju pred in med zdravljenjem ter o preprečevanju nosečnosti in učinkoviti kontracepciji pri bolnicah in bolnikih.
The study compared the effect of Mavenclad and placebo (a dummy treatment) in reducing the relapse rate 96 weeks after the start of treatment. 
V študiji so primerjali učinek zdravila Mavenclad in placeba (zdravila brez zdravilne učinkovine) pri zmanjševanju stopnje ponovitve 96 tednov po začetku zdravljenja.
Patients treated with Mavenclad had a relapse rate of 0.14 per year on average, compared with 0.33 for patients given placebo; at the end of 96 weeks, around 8 out 10 patients given standard doses of Mavenclad and 6 out of 10 given placebo had not had a relapse. 
Pri bolnikih, zdravljenih z zdravilom Mavenclad, je bila stopnja ponovitve povprečno 0,14 na leto, v primerjavi z 0,33 pri bolnikih, ki so prejemali placebo; po preteku 96 tednov do ponovitve ni prišlo pri 8 bolnikih od 10, ki so prejemali standardne odmerke zdravila Mavenclad, in 6 bolnikih od 10, ki so prejemali placebo.
The dose depends on patients' body weight and treatment consists of two courses spread over 2 years. 
Odmerek je odvisen od telesne mase bolnika, zdravljenje pa je sestavljeno iz dveh ciklov v času dveh let.
Mavenclad has been shown to be effective in one main study involving 1,326 patients with relapsingremitting multiple sclerosis. 
Zdravilo Mavenclad se je kot učinkovito pokazalo v eni glavni študiji, v katero je bilo vključenih 1 326 bolnikov z recidivno-remitentno multiplo sklerozo.
In multiple sclerosis, the body's immune (defence) system attacks and damages the protective sheath around the nerve cells in the central nervous system (the brain and spinal cord). 
Pri multipli sklerozi imunski (obrambni) sistem telesa napade in poškoduje zaščitno ovojnico okoli živčnih celic v osrednjem živčevju (možganih in hrbtenjači).
In addition, patients given Mavenclad were nearly 50% less likely to have disease progression (indicated as an increase in disability that lasted for at least 6 months). 
Poleg tega je bilo napredovanje bolezni skoraj 50 % manj verjetno pri bolnikih, ki so prejemali zdravilo Mavenclad (opredeljeno kot povečanje nezmožnosti, ki je trajalo vsaj 6 mesecev).